The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies
Open accessAbstract
Polymer nanoparticles (NPs) represent one of the most innovative non-invasive approaches for drug delivery applications. NPs main objective is to convey the therapeutic molecule be they drugs, proteins, or nucleic acids directly into the target organ or tissue. Many polymers are used for the synthesis of NPs and among the currently most employed materials several biocompatible synthetic polymers, namely polylactic acid (PLA), poly lactic-co-glycolic acid (PLGA), and polyethylene glycol (PEG), can be cited. These molecules are made of simple monomers which are naturally present in the body and therefore easily excreted without being toxic. The present review addresses the different approaches that are most commonly adopted to synthetize biocompatible NPs to date, as well as the experimental strategies designed to load them with therapeutic agents. In fact, drugs may be internalized in the NPs or physically dispersed therein. In this paper the various types of biodegradable polymer NPs will be discussed with emphasis on their applications in drug delivery. Close attention will be devoted to the treatment of cancer, where both active and passive targeting is used to enhance efficacy and reduce systemic toxicity, and to diseases affecting the central nervous system, inasmuch as NPs can be modified to target specific cells or cross membrane barriers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816 · cited 5×
“Depending on the nozzle size, flow rate, and solution viscosity, the properties of polymer NPs can be controlled [7,13].”
BackgroundInfluentialLong-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Biomedical applications of biodegradable polymers
Ulery, B. D., Nair, L. S., & Laurencin, C. T. (2011) · Journal of Polymer Science Part B: Polymer Physics · doi:10.1002/polb.22259 · Cited by 2,206 · cited 2×
“The use of biod gra able NPs is therefore aimed at “drug targeting”, that is, the selective transp t of a therapeutic age t to i s action site independently of the compartment r th m tho of administration [6].”
BackgroundTumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Structure and design of polymeric surfactant-based drug delivery systems
Torchilin, V. P. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00299-1 · Cited by 1,822
Cited by
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., et al. (2020) · Molecules · doi:10.3390/molecules25163731 · Cited by 1,560
Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects
Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., & Alcudia, A. (2020) · Nanomaterials · doi:10.3390/nano10071403 · Cited by 1,061
PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application
Su, Y., Zhang, B., Sun, R., Liu, W., Zhu, Q., Zhang, X., Wang, R., & Chen, C. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1938756 · Cited by 617
Brown, T. P., & Ganapathy, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107451 · Cited by 481
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer
Sharma, P., Mehta, M., Dhanjal, D. S., Kaur, S., Gupta, G., Singh, H., Thangavelu, L., Rajeshkumar, S., Tambuwala, M., Bakshi, H. A., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.06.033 · Cited by 430
De, R., Mahata, M. K., & Kim, K. (2022) · Advanced Science · doi:10.1002/advs.202105373 · Cited by 297
Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
Avramović, N., Mandić, B., Savić-Radojević, A., & Simić, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040298 · Cited by 296
Ahlawat, J., Guillama Barroso, G., Masoudi Asil, S., Alvarado, M., Armendariz, I., Bernal, J., Carabaza, X., Chavez, S., Cruz, P., Escalante, V., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01592 · Cited by 274
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Hu, D., Li, Y., Li, R., Wang, M., Zhou, K., He, C., Wei, Q., & Qian, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.015 · Cited by 153
Microglia-targeting nanotherapeutics for neurodegenerative diseases
Zhao, N., Francis, N. L., Calvelli, H. R., & Moghe, P. V. (2020) · APL Bioengineering · doi:10.1063/5.0013178 · Cited by 104
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Clinical translation of nanomedicines for brain diseases: Current challenges and future directions
Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33
New perspectives on arteriosclerosis treatment using nanoparticles and mesenchymal stem cells
Farokhi, S., Razavi, Z.-S., Mavaei, M., Shadab, A., Afkhami, H., & Sardarabadi, H. (2024) · Discover Applied Sciences · doi:10.1007/s42452-024-06113-8 · Cited by 27
Metadata
- Authors
- Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., & Emiliani, C.
- Venue
- Journal of Functional Biomaterials
- Publisher
- MDPI AG
- Published
- 2019-01-08
- Volume
- 10
- Issue
- 1
- Pages
- 4
- ISSN
- 2079-4983 (ISSN-L)
- OpenAlex
- W2910966398
- Cited by
- 468
- References
- 94
- FWCI
- 14.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.